Takemasa Tsuji to CD8-Positive T-Lymphocytes
This is a "connection" page, showing publications Takemasa Tsuji has written about CD8-Positive T-Lymphocytes.
Connection Strength
1.788
-
Antibody-targeted NY-ESO-1 to mannose receptor or DEC-205 in vitro elicits dual human CD8+ and CD4+ T cell responses with broad antigen specificity. J Immunol. 2011 Jan 15; 186(2):1218-27.
Score: 0.294
-
Trans-vaccenic acid reprograms CD8+ T cells and anti-tumour immunity. Nature. 2023 Nov; 623(7989):1034-1043.
Score: 0.180
-
An efficient method to prepare T cell receptor gene-transduced cytotoxic T lymphocytes type 1 applicable to tumor gene cell-therapy. Cancer Sci. 2003 Apr; 94(4):389-93.
Score: 0.173
-
Tissue residency of memory CD8+ T cells matters in shaping immunogenicity of ovarian cancer. Cancer Cell. 2022 05 09; 40(5):452-454.
Score: 0.162
-
Tcf-1 protects anti-tumor TCR-engineered CD8+ T-cells from GzmB mediated self-destruction. Cancer Immunol Immunother. 2022 Dec; 71(12):2881-2898.
Score: 0.162
-
CXCR6 by increasing retention of memory CD8+ T cells in the ovarian tumor microenvironment promotes immunosurveillance and control of ovarian cancer. J Immunother Cancer. 2021 10; 9(10).
Score: 0.156
-
Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer. J Immunother Cancer. 2019 06 20; 7(1):156.
Score: 0.133
-
A rare population of tumor antigen-specific CD4+CD8+ double-positive aß T lymphocytes uniquely provide CD8-independent TCR genes for engineering therapeutic T cells. J Immunother Cancer. 2019 01 09; 7(1):7.
Score: 0.129
-
Split T cell tolerance against a self/tumor antigen: spontaneous CD4+ but not CD8+ T cell responses against p53 in cancer patients and healthy donors. PLoS One. 2011; 6(8):e23651.
Score: 0.077
-
Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A. 2010 Apr 27; 107(17):7875-80.
Score: 0.070
-
Critical role of the Th1/Tc1 circuit for the generation of tumor-specific CTL during tumor eradication in vivo by Th1-cell therapy. Cancer Sci. 2003 Oct; 94(10):924-8.
Score: 0.045
-
Successful elimination of memory-type CD8+ T cell subsets by the administration of anti-Gr-1 monoclonal antibody in vivo. Cell Immunol. 2003 Aug; 224(2):98-105.
Score: 0.044
-
BiTE secretion by adoptively transferred stem-like T cells improves FRa+ ovarian cancer control. J Immunother Cancer. 2023 06; 11(6).
Score: 0.044
-
WHSC1/NSD2 regulates immune infiltration in prostate cancer. J Immunother Cancer. 2021 02; 9(2).
Score: 0.037
-
Direct tumor recognition by a human CD4(+) T-cell subset potently mediates tumor growth inhibition and orchestrates anti-tumor immune responses. Sci Rep. 2015 Oct 08; 5:14896.
Score: 0.026
-
Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clin Cancer Res. 2012 Dec 01; 18(23):6497-508.
Score: 0.021
-
Phase I clinical trial of mixed bacterial vaccine (Coley's toxins) in patients with NY-ESO-1 expressing cancers: immunological effects and clinical activity. Clin Cancer Res. 2012 Oct 01; 18(19):5449-59.
Score: 0.021
-
Inducing efficient cross-priming using antigen-coated yeast particles. J Immunother. 2008 Sep; 31(7):607-19.
Score: 0.016